References

Basak, A., Hancarova, M., Ulirsch, J. C., Balci, T. B., Trkova, M., Pelisek, M., Vlckova, M., Muzikova, K., Cermak, J., Trka, J., Dyment, D. A., Orkin, S. H., Daly, M. J., Sedlacek, Z., & Sankaran, V. G. (2015). BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations. The Journal of clinical investigation, 125(6), 2363–2368. https://doi.org/10.1172/JCI81163

Bock, C., Datlinger, P., Chardon, F., Coelho, M. A., Dong, M. B., Lawson, K. A., Lu, T., Maroc, L., Norman, T. M., Song, B., Stanley, G., Chen, S., Garnett, M., Li, W., Moffat, J., Qi, L. S., Shapiro, R. S., Shendure, J., Weissman, J. S., & Zhuang, X. (2022). High-content CRISPR screening. Nature Reviews Methods Primers, 2(1). https://doi.org/10.1038/s43586-021-00093-4

CRISPR Editing is All About DNA Repair Mechanisms. (2019, May 30). Synthego. https://www.synthego.com/blog/crispr-dna-repair-pathways

Davies, K., PhD. (2024, February 1). FDA approves the first CRISPR therapy for sickle cell disease. GEN - Genetic Engineering and Biotechnology News. https://www.genengnews.com/topics/genome-editing/fda-approves-the-first-crispr-therapy-for-sickle-cell-disease/

Davies, K., & Church, G. M. (2019). Radical Technology Meets Radical Application: An Interview with George Church. The CRISPR Journal, 2(6), 346–351. https://doi.org/10.1089/crispr.2019.29074.gch

DeWitt, J., PhD. (n.d.). CRISPR off-target detection with NGS. Integrated DNA Technologies. https://www.idtdna.com/pages/technology/crispr/crispr-genome-editing/crispr-detection/next-generation-sequencing

Doudna, J.A. (2022). CRISPR in Nature. In M.L. Hochstrasser et al. (Eds.) CRISPRpedia. Berkeley: Innovative Genomics Institute, University of California, Berkeley. https://innovativegenomics.org/crisprpedia/crispr-in-nature/

Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature, 551(7681), 464–471. https://doi.org/10.1038/nature24644

Genetic Literacy Project. (2019, December 31). United States: Germline / embryonic. Global Gene Editing Regulation Tracker. https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/

Gleditzsch, D., Pausch, P., Müller-Esparza, H., Özcan, A., Guo, X., Bange, G., & Randau, L. (2019). PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures. RNA biology, 16(4), 504–517. https://doi.org/10.1080/15476286.2018.1504546

Gostimskaya I. (2022). CRISPR-Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing. Biochemistry. Biokhimiia, 87(8), 777–788. https://doi.org/10.1134/S0006297922080090

HIV/AIDS Glossary. (n.d.). Binding. HIV.gov. https://clinicalinfo.hiv.gov/en/glossary/binding

Ishino, Y., Krupovic, M., & Forterre, P. (2018). History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology. Journal of bacteriology, 200(7), e00580-17. https://doi.org/10.1128/JB.00580-17

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of bacteriology, 169(12), 5429–5433. https://doi.org/10.1128/jb.169.12.5429-5433.1987

Lewis, T. (2023, October 18). Milestone pig-to-human heart transplant may pave the way for broader trial. Scientific American. https://www.scientificamerican.com/article/milestone-pig-to-human-heart-transplant-may-pave-the-way-for-broader-trial/

Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P. F., & Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. Signal transduction and targeted therapy, 8(1), 36. https://doi.org/10.1038/s41392-023-01309-7

MacMillan, C. (2023, December 19). Casgevy and Lyfgenia: two gene therapies approved for sickle cell disease. Yale Medicine. https://www.yalemedicine.org/news/gene-therapies-sickle-cell-disease

Mohiuddin, M. M., Singh, A. K., Scobie, L., Goerlich, C. E., et al. (2023). Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet (London, England), 402(10399), 397–410. https://doi.org/10.1016/S0140-6736(23)00775-4

Mojica, F. J., Juez, G., & Rodríguez-Valera, F. (1993). Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Molecular microbiology, 9(3), 613–621. https://doi.org/10.1111/j.1365-2958.1993.tb01721.x

Morgens, D. W., Deans, R. M., Li, A., & Bassik, M. C. (2016). Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nature biotechnology, 34(6), 634–636. https://doi.org/10.1038/nbt.3567

Office of the Commissioner. (2023, December 8). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

Peng, R., Lin, G., & Li, J. (2016). Potential pitfalls of CRISPR/Cas9-mediated genome editing. The FEBS journal, 283(7), 1218–1231. https://doi.org/10.1111/febs.13586

Perez, A. R., Pritykin, Y., Vidigal, J. A., Chhangawala, S., Zamparo, L., Leslie, C. S., & Ventura, A. (2017). GuideScan software for improved single and paired CRISPR guide RNA design. Nature Biotechnology, 35(4), 347–349. https://doi.org/10.1038/nbt.3804

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nature protocols, 8(11), 2281–2308. https://doi.org/10.1038/nprot.2013.143

Raposo V. L. (2019). The First Chinese Edited Babies: A Leap of Faith in Science. JBRA assisted reproduction, 23(3), 197–199. https://doi.org/10.5935/1518-0557.20190042

Reuven, N., & Shaul, Y. (2022). Selecting for CRISPR-Edited Knock-In Cells. International journal of molecular sciences, 23(19), 11919. https://doi.org/10.3390/ijms231911919

Ryczek, N., Hryhorowicz, M., Zeyland, J., Lipinski, D., & Slomski, R. (2021). CRISPR/Cas Technology in Pig-to-Human Xenotransplantation Research. International journal of molecular sciences, 22(6), 3196. https://doi.org/10.3390/ijms22063196

Shapiro, L. (2023, December 21). Bluebird set for Lyfgenia's launch after 'remarkable' approvals. Sickle Cell Disease News. https://sicklecellanemianews.com/news/bluebird-set-lyfgenias-launch-after-remarkable-gene-therapy-approvals/

Study identifies pitfall for correcting mutations in human embryos. (2020, November 4). Columbia University Irving Medical Center. https://www.cuimc.columbia.edu/news/study-identifies-pitfall-correcting-mutations-human-embryos-crispr

Wang, W., He, W., Ruan, Y., & Geng, Q. (2022). First pig-to-human heart transplantation. Innovation(Cambridge (Mass.)), 3(2), 100223. https://doi.org/10.1016/j.xinn.2022.100223

Westermann, L., Neubauer, B., & Köttgen, M. (2021). Nobel Prize 2020 in Chemistry honors CRISPR: a tool for rewriting the code of life. Pflugers Archiv: European journal of physiology, 473(1), 1–2. https://doi.org/10.1007/s00424-020-02497-9

What are genome editing and CRISPR-Cas9? (Updated 2022, Mar 22). MedlinePlus Genetics. https://medlineplus.gov/genetics/understanding/genomicresearch/genomeediting/

Xue, C., & Greene, E. C. (2021). DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing. Trends in genetics: TIG, 37(7), 639–656. https://doi.org/10.1016/j.tig.2021.02.008